White House Announces Largest Drug Pricing Deals Yet
Tap title to read story
WASHINGTON — The Trump administration announced agreements with nine drugmakers to lower U.S. prescription prices and expand domestic manufacturing. Companies pledged to cut Medicaid prices to levels paid in peer nations, launch new drugs at comparable global prices, and distribute discounts through a TrumpRx platform. The deals raised the total to 14 firms and include donations of bulk active pharmaceutical ingredients to a national reserve — Merck (ertapenem), Bristol Myers Squibb (apixaban) and GSK (albuterol). Three targeted firms have not yet signed. Agreements link price cuts to tariff relief and reshoring incentives. Per reports. Based on 6 articles reviewed and supporting research.
More context
Timeline
- 1. Summer: Administration identified and targeted 17 drugmakers for pricing negotiations.
- 2. Earlier this year: Several companies (including Pfizer and AstraZeneca) struck initial price-reduction agreements.
- 3. Dec 20: White House announced nine additional company agreements, bringing total signatories to 14.
- 4. Dec 20: Some signatories pledged donations of bulk active ingredients to a Strategic API Reserve.
- 5. Dec 20: Administration linked price concessions to tariff relief and announced a planned TrumpRx consumer discount platform.
Sources
JQJO Editorial Desk · Human reviewed · AI assisted. Report a correction.
